Zantac Effervescent Tablets 150mg

  • Name:

    Zantac Effervescent Tablets 150mg

  • Company:
    info
  • Active Ingredients:

    Ranitidine Hydrochloride

  • Legal Category:

    Product subject to medical prescription which may be renewed (B)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 11/09/18

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 11/9/2018

Click on this link to Download PDF directly

GlaxoSmithKline (Ireland) Ltd

GlaxoSmithKline (Ireland) Ltd

Company Products

Medicine NameActive Ingredients
Medicine Name Lamictal 5mg chewable/dispersible tablets Active Ingredients Lamotrigine
Medicine Name Lyclear Dermal Cream Active Ingredients Permethrin
Medicine Name Malarone Film Coated Tablets Active Ingredients Atovaquone, Proguanil Hydrochloride
Medicine Name Menitorix powder and solvent for solution for injection Active Ingredients Hib/Meningococcal group C combined vaccine
Medicine Name MENJUGATE 10 micrograms suspension for injection (PFS) Active Ingredients Meningococcal group C conjugate vaccine
Medicine Name Menveo, powder and solution for solution for injection Active Ingredients Meningococcal Group A, C, W135 and Y conjugate vaccine
Medicine Name Nucala 100 mg powder for solution for injection Active Ingredients Mepolizumab
Medicine Name Phymet DTF 1mg/ml Syrup Active Ingredients Methadone Hydrochloride
Medicine Name Priorix – Powder and solvent for solution for injection in a pre-filled syringe Active Ingredients Measles Vaccine, Mumps Vaccine, Rubella Vaccine
Medicine Name Relvar Ellipta 184 micrograms/22 micrograms inhalation powder, pre-dispensed Active Ingredients Fluticasone furoate, Vilanterol trifenatate
Medicine Name Relvar Ellipta 92 micrograms/22 micrograms inhalation powder, pre-dispensed Active Ingredients Fluticasone furoate, Vilanterol trifenatate
Medicine Name Requip 0.25 mg film-coated tablets Active Ingredients ropinirole hydrochloride
Medicine Name Requip 1 mg film-coated tablets Active Ingredients ropinirole hydrochloride
Medicine Name Requip 2 mg film-coated tablets Active Ingredients ropinirole hydrochloride
Medicine Name Requip 5 mg film-coated tablets Active Ingredients ropinirole hydrochloride
Medicine Name Requip-Modutab 2 mg prolonged-release tablets Active Ingredients ropinirole hydrochloride
Medicine Name Requip-Modutab 4 mg prolonged-release tablets Active Ingredients ropinirole hydrochloride
Medicine Name Requip-Modutab 8 mg prolonged-release tablets Active Ingredients ropinirole hydrochloride
Medicine Name Rotarix oral suspension in pre-filled oral applicator Active Ingredients Live attenuated rotavirus vaccine
Medicine Name Seretide Diskus Active Ingredients Fluticasone Propionate, Salmeterol Xinafoate
Medicine Name Seretide Evohaler Active Ingredients Fluticasone Propionate, Salmeterol Xinafoate
Medicine Name Serevent Diskus Active Ingredients Salmeterol Xinafoate
Medicine Name Serevent Evohaler Active Ingredients Salmeterol Xinafoate
Medicine Name Seroxat Liquid Active Ingredients Paroxetine hydrochloride hemihydrate
Medicine Name Seroxat Tablets Active Ingredients Paroxetine hydrochloride hemihydrate
76 - 100 of 136 items.Total: 6 pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 11 September 2018 PIL

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 2 - excipient warnings
  • Change to section 6 - what the product contains
  • Change to section 6 - date of revision
  • Correction of spelling/typing errors
  • Change to improve clarity and readability

Updated on 11 September 2018 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 2 - Changes quantity of sodium from 328mg to 327mg
Section 4.4:
Addition of sodium warning: This medicinal product contains 327 mg sodium per dose, equivalent to 16% of the WHO recommended maximum daily intake for sodium.
The maximum daily dose of this product is equivalent to 65% of the WHO recommended maximum daily intake for sodium.
Zantac Effervescent Tablets is considered high in sodium. This should be particularly taken into account for those on a low salt diet.

 

Updated on 22 July 2015 PIL

Reasons for updating

  • New PIL for new product

Updated on 22 July 2015 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 22 July 2015 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Change to address of the Irish MA Holder

Updated on 22 July 2015 PIL

Reasons for updating

  • Change to date of revision
  • Change to MA holder contact details

Updated on 17 June 2015 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 4.9 - Overdose
  • Change to section 10 - Date of revision of the text
  • Change to improve clarity and readability

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.4: H2 receptor antagonists changed to ranitidine alone.
Section 4.5: Amended to include information on interaction between ranitidine and amoxicillin and metronidazole.
Section 4.8: Dyspnoea included as unknown adverse event under Immune System Disorders. Tachycardia added as very rare adverse event under Cardiac Disorders. Nephropatic patients referenced under Psychiatric Disorders. Paediatric subheading and adverse event reporting details included

Updated on 16 June 2015 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to storage instructions
  • Change to side-effects
  • Change to drug interactions
  • Change to date of revision
  • Change to improve clarity and readability
  • Addition of information on reporting a side effect.

Updated on 2 May 2014 SmPC

Reasons for updating

  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 6.1 - List of excipients
  • Change to section 6.3 - Shelf life
  • Change to section 6.4 - Special precautions for storage
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

4.3

QRD statement for hypersensitivity

4.4

Update to the warnings

4.5

Change to the information regarding one of the medicines that interacts

4.6

Rewording of this section

6.1

Update to the excipients

6.3

Shelf life is 2 years – previously approved in another variation

6.4

Storage conditions do not store above 25 degrees – previously approved in another variation

Updated on 1 May 2014 PIL

Reasons for updating

  • Correction of spelling/typing errors

Updated on 29 April 2014 PIL

Reasons for updating

  • Correction of spelling/typing errors

Updated on 23 January 2014 SmPC

Reasons for updating

  • Change to section 6.3 - Shelf life

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Change to:

 

 

Section 6.3 - Shelf life

 

Updated on 23 October 2012 SmPC

Reasons for updating

  • Change to section 6.4 - Special precautions for storage

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

 

 

6.4 Special precautions for storage

 

Do not store above 2530°C

Tubes: Keep container tightly closed in order to protect from light and moisture.

 

10.  DATE OF (PARTIAL) REVISION OF THE TEXT

 

July 2011July 2012

Updated on 19 October 2012 PIL

Reasons for updating

  • Change to storage instructions

Updated on 20 December 2011 PIL

Reasons for updating

  • Change due to user-testing of patient information

Updated on 5 July 2011 SmPC

Reasons for updating

  • Change to section 3 - Pharmaceutical form

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company


3.  PHARMACEUTICAL FORM

 

Effervescent tablet.

 

A white to pale yellow, round bevelled tablet marked “GS LHK” on one side and flat on the other which effervesces on dissolution in water to give a clear orange/grapefruit flavoured solution.

Updated on 5 July 2011 PIL

Reasons for updating

  • Change of manufacturer

Updated on 9 June 2011 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.2 - Pharmacokinetic properties

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

4.2       Posology and Method of Administration

 

 

 

Renal Insufficiency:

 

In patients with a creatinine clearance < 50ml/min the usual dose is 150mg nightly.  In patients on dialysis, dosage should be given on completion of dialysis.

Accumulation of ranitidine with resulting elevated plasma concentrations will occur in patients with renal impairment (creatinine clearance less than 50 ml/min). It is recommended that the daily dose of ranitidine in such patients should be 150 mg.

**************************************************************

 

4.4  Special warnings and precautions for use

 

Before initiation of ranitidine treatment for any gastric ulceration, malignancy should be excluded by endoscopy and biopsy if possible.  Treatment may mask the symptoms of malignancy, delaying diagnosis.

 

Ranitidine is excreted via the kidney and so plasma levels of the drug are increased in patients with severe renal impairment, adjust dosage detailed under section 4.2 above.

 

Regular supervision of patients who are taking non-steroidal anti-inflammatory drugs concomitantly with ranitidine is recommended, especially in the elderly and in those with a history of peptic ulcer.

 

In patients such as the elderly, persons with chronic lung disease, diabetes orf the immunocompromised, there may be an increased risk of developing community acquired pneumonia. A large epidemiological study showed an increased risk of developing community acquired pneumonia in current users of H2 receptor antagonistsranitidine alone versus those who had stopped treatment, with an observed adjusted relative risk of 1.63 (95% CI, 1.07-2.48)increase of 1.82 (95% CI 1.26 – 2.64).

 

**************************************************************

 

 

4.6  Fertility, Ppregnancy and lactation

 

**************************************************************

 

4.8  Undesirable effects

 

 

Gastrointestinal Disorders

Very Rare:       Acute pancreatitis. Diarrhoea.

Uncommon:     Abdominal pain, constipation, nausea (these symptoms mostly improved during continued treatment)

 

 

Renal and Urinary Disorders

Very rare:        Acute interstitial nephritis.

Rare:                Elevation of plasma creatinine (usually slight; normalised during continued treatment).

 

Reproductive System and Breast Disorders

Very Rare:       Reversible impotence. Breast symptoms in men, breast symptoms and breast conditions (such as gynaecomastia and galactorrhoea)

 

**************************************************************

 

5.  PHARMACOLOGICAL PROPERTIES

 

 

5.2  Pharmacokinetic properties

 

The bioavailability of ranitidine is consistently about 50%.  Peak concentrations in plasma, normally in the range 300-550ng/ml, occur 2-3 hours after oral administration of a 150mg dose.  Concentrations of ranitidine in plasma are proportional to dose up to and including 300mg.  Ranitidine is not extensively metabolised.  Elimination of the drug is primarily by tubular secretion.  The elimination half-life is 2-3 hours.  In balance studies with 150mg 3H-ranitidine 93% of an intravenous dose was excreted in urine and 5% in faeces; 60-70% of an oral dose was excreted in urine and 26% in faeces. 

 

Analysis of urine excreted in the first 24 hours after dosing showed that 70% of the intravenous dose and 35% of the oral dose were eliminated unchanged. 

 

The metabolism of ranitidine is similar after both oral and intravenous dosing; about 6% of the dose being excreted in urine as the N-oxide, 2% as the S-oxide, 2% as desmethylranitidine and  1 - 2% as the furoic acid analogue.

 

Absorption:

Following oral administration of 150 mg ranitidine, maximum plasma concentrations (300 to 550 ng/mL) occurred after 1-3 hours. Two distinct peaks or a plateau in the absorption phase result from reabsorption of drug excreted into the intestine. The absolute bioavailability of ranitidine is 50-60%, and plasma concentrations increase proportionally with increasing dose up to 300 mg.

 

Distribution:

Ranitidine is not extensively bound to plasma proteins (15%), but exhibits a large volume of distribution ranging from 96 to 142 L.

 

Metabolism:

Ranitidine is not extensively metabolised. The fraction of the dose recovered as metabolites is similar after both oral and i.v. dosing; and include 6% of the dose in urine as N-oxide, 2% as the S-oxide, 2% as desmethylranitidine and 1 to 2% as the furoic acid analogue.

 

Elimination:

Plasma concentrations decline bi-exponentially, with a terminal half-life of 2-3 hours. The major route of elimination is renal. After IV administration of 150 mg 3H-ranitidine, 98% of the dose was recovered, including 5% in faeces and 93% in urine, of which 70% was unchanged parent drug. After oral administration of 150 mg 3H-ranitidine, 96% of the dose was recovered, 26% in faeces and 70% in urine, of which 35% was unchanged parent drug. Less than 3% of the dose is excreted in bile. Renal clearance is approximately 500 mL/min, which exceeds glomerular filtration indicating net renal tubular secretion.

 

Updated on 7 February 2011 PIL

Reasons for updating

  • Change to storage instructions

Updated on 18 November 2010 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 6.4 - Special precautions for storage
  • Change to section 6.5 - Nature and contents of container
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

 

 

 

SUMMARY OF PRODUCT CHARACTERISTICS

 

 

1. NAME OF THE MEDICINAL PRODUCT

 

Zantac 150mg Effervescent Tablets

 

2.  QUALITATIVE AND QUANTITATIVE COMPOSITION

 

Each effervescent tablet contains 150mg ranitidine (as hydrochloride)

Excipients – contains Aspartame (E951) 30.0mg, Sorbitol (E420) approximately 1.14mg and Sodium 328mg

For a full list of excipients, see section 6.1

 

*************************************************************

 

4.  CLINICAL PARTICULARS

 

 

4.4  Special warnings and special precautions for use

 

Before initiation of ranitidine treatment for any gastric ulceration, malignancy should be excluded by endoscopy and biopsy if possible.  Treatment may mask the symptoms of malignancy, delaying diagnosis.

 

Ranitidine is excreted via the kidney and so plasma levels of the drug are increased in patients with severe renal impairment, adjust dosage detailed under section 4.2 above.

 

Regular supervision of patients who are taking non-steroidal anti-inflammatory drugs concomitantly with ranitidine is recommended, especially in the elderly and in those with a history of peptic ulcer.

 

In patients such as the elderly, persons with chronic lung disease, diabetes of the immunocompromised, there may be an increased risk of developing community acquired pneumonia. A large epidemiological study showed an increased risk of developing community acquired pneumonia in current users of H2 receptor antagonists versus those who had stopped treatment, with an observed adjusted relative risk of 1.63 (95% CI, 1.07-2.48)

 

Zantac Effervescent Tablets contain 14.3mEq (328mg) of sodium.  Care should therefore be taken in treating patients in whom sodium restriction is indicated.

 

As Zantac Effervescent Tablets contain aspartame they should be used with caution in patients with phenylketonuria.

 

Patients with rare hereditary problems of fructose intolerance should not take this medicine.

 

Rare clinical reports suggest that ranitidine may precipitate acute porphyric attacks.  Ranitidine should therefore be avoided in patients with a history of acute porphyria.

 

In keeping with the recommended clinical practice it is advisable that patients on long-term maintenance therapy receive regular routine assessment by practitioners.

 

*************************************************************

 

6.  PHARMACEUTICAL PARTICULARS

 

 

6.4 Special precautions for storage

 

Do not store above 30°C

Tubes: Keep container tightly closed in order to protect from light and moisture.

 

Blisters: Store in the original package

 

*************************************************************

 

6.5  Nature and contents of containers

 

Zantac Effervescent Tablets 150mg are packed in white polypropylene tubes fitted with white polyethylene caps filled with silica gel.  The Two tubes are packed into a cardboard carton which has a tamper evident closure.  Each tube contains 15 tablets. Alternatively one tube of 10 tablets is packed into a cardboard carton which has a tamper evident closure.

 

Not all pack sizes may be marketed.

 

Alternatively, Zantac effervescent tablets 150mg are packed in heat-sealable aluminium foil strips. Each aluminium foil strip contains six tablets and five of these strips are packed into a cardboard carton, which has a tamper evident closure.

 

A sample pack of 6 tablets in a foil strip is also available

 

*************************************************************

 

6.6  Special precautions for disposal of a used medicinal product or waste materials derived from such medicinal product and other handling of the product Instructions for use and handling

 

One or two Zantac Effervescent Tablets should be dissolved in half a tumbler of water (at least 75ml) and stirred thoroughly until completely dissolved before swallowing.

 

*************************************************************

 

9.  DATE OF FIRST AUTHORISATION/RENEWAL OF AUTHORISATION

 

Date of first authorisation: 27 June 1990

Date of last renewal: 27 June 2010

 

*************************************************************

 

10.  DATE OF (PARTIAL) REVISION OF THE TEXT

 

November 2010

Updated on 20 April 2010 SmPC

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

4.1  Therapeutic indications

 

In the treatment of duodenal ulcer and benign gastric ulcer including that associated with non-steroidal anti-inflammatory agents.  Prevention of non-steroidal anti-inflammatory drug (including aspirin) associated duodenal ulcers, especially in patients with a history of peptic ulcer disease.  Zantac Tablets are also indicated for treatment of post-operative ulcer, reflux oesophagitis, Zollinger-Ellison syndrome and other conditions where reduction of gastric acid secretion is likely to be beneficial.

 

Children (3 to 18 years)

 

·                Short term treatment of peptic ulcer

·                Treatment of gastro-oesophageal reflux, including reflux oesophagitis and symptomatic relief of gastro-oesophageal reflux disease.

 

4.2       Posology and Method of Administration

 

Adults (including the elderly) / Adolescents (12 years and over)

 

The usual initial dosage is 150mg bd or 300mg nocte.  This may be increased to ranitidine 300mg twice daily without an increased incidence of unwanted effects.  Subsequently a maintenance dose of 150mg nocte may be used.  Smoking is associated with a higher rate of ulcer relapse, and such patients should be advised to stop smoking.  In those who fail to comply with such advice, a dose of 300mg at night provides additional therapeutic benefit over the standard dose.

 

In most cases of duodenal ulcer, benign gastric ulcer and post operative ulcer, healing occurs within 4 weeks.  Healing usually occurs after a further 4 weeks in those not fully healed after the initial 4 weeks.  In ulcers following non-steroidal anti-inflammatory drug therapy, 8 - 12 weeks treatment may be necessary.  For the prevention of non-steroidal anti-inflammatory drug associated duodenal ulcers ranitidine 150mg bd may be given concomitantly with non-steroidal anti-inflammatory drug therapy.

 

In the management of reflux oesophagitis the usual course of treatment is either 150mg twice daily or 300mg at night administered for up to a period of 8, or if necessary 12 weeks.  In patients with moderate to severe oesophagitis the dosage may be increased to 150mg four times daily, alternatively 300mg twice a day, if necessary.

 

For the long-term management of reflux oesophagitis, the recommended adult oral dose is 150mg twice daily for the prevention of relapse in patients with reflux oesophagitis.  Zantac 150mg effervescent tablets are not indicated in patients with complications of reflux oesophagitis e.g. severe oesophegeal stricture or Barratt’s oesophagus.

 

In keeping with the recommended clinical practice it is advisable that patients on long-term maintenance therapy receive regular routine assessment by practitioners.

 

In patients with Zollinger-Ellison syndrome the starting dose is 150mg thrice daily, increased as necessary up to a maximum of 6 grams daily.

 

In the prophylaxis of haemorrhage from stress ulceration in seriously ill patients or the prophylaxis of recurrent haemorrhage in patients bleeding from peptic ulceration, treatment with Zantac 150mg twice daily may be substituted for Zantac Injection once oral feeding commences in patients considered to be still at risk from these conditions.

 

In obstetric patients an oral dose of 150mg may be given at commencement of labour, followed by 150mg at 6 hourly intervals.  It is recommended that in addition, a non-particulate antacid (eg sodium citrate) should be given prior to induction of anaesthesia in any patient requiring emergency general anaesthesia.

 

Children from 3 to 11 years and over 30 kg of weight

 

See section 5.2 Pharmacokinetic properties – Special Patient Populations.

 

Peptic Ulcer Acute Treatment

 

The recommended oral dose for the treatment of peptic ulcer in children is 4 mg/kg/day to 8 mg/kg/day administered as two divided doses to a maximum of 300 mg ranitidine per day for a duration of 4 weeks. For those patients with incomplete healing, another 4 weeks of therapy is indicated, as healing usually occurs after eight weeks of treatment.

 

Gastro-Oesophageal Reflux

 

The recommended oral dose for the treatment of gastro-oesophageal reflux in children is 5 mg/kg/day to 10 mg/kg/day administered as two divided doses in a maximum dose of 600 mg (the maximum dose is likely to apply to heavier children or adolescents with severe symptoms).

 

Safety and efficacy in new-born patients has not been established

 

The recommended oral dose for the treatment of peptic ulcer in children is 2mg/kg to 4mg/kg twice daily to a maximum of 300mg ranitidine per day.

 

4.5  Interaction with Other Medicaments and Other Forms of Interaction

 

Ranitidine has the potential to affect the absorption, metabolism or renal excretion of other drugs.  The altered pharmacokinetics may necessitate dosage adjustment of the affected drug or discontinuation of treatment.

 

Interactions occur by several mechanisms including:

 

1) Inhibition of cytochrome P450-linked mixed function oxygenase system:

Ranitidine at usual therapeutic doses does not potentiate the actions of drugs which are inactivated by this enzyme system such as diazepam, lidocaine, phenytoin, propranolol and theophylline. 

There have been reports of altered prothrombin time with coumarin anticoagulants (e.g. warfarin). Due to the narrow therapeutic index, close monitoring of increased or decreased prothrombin time is recommended during concurrent treatment with ranitidine.

 

2) Competition for renal tubular secretion:

Since ranitidine is partially eliminated by the cationic system, it may affect the clearance of other drugs eliminated by this route.  High doses of ranitidine (e.g such as those used in the treatment of Zollinger-Ellison syndrome) may reduce the excretion of procainamide and N-acetylprocainamide resulting in increased plasma levels of these drugs.

 

3) Alteration of gastric pH:

The bioavailability of certain drugs may be affected.  This can result in either an increase in absorption (e.g. triazolam, midazolam) or a decrease in absorption (e.g. ketoconazole, atazanavir, glipizide, delaviridine, gefitnib).

 

Ranitidine, at blood levels produced by standard recommended doses, does not inhibit the hepatic cytochrome P450-linked mixed function oxygenase system.  Accordingly, ranitidine in the usual therapeutic dose does not potentiate the actions of drugs which are inactivated by this enzyme; these include diazepam, lignocaine, phenytoin, propranolol, theophylline and warfarin.

 

……………………………..

4.8  Undesirable effects

 

The following convention has been utilised for the classification of undesirable effects: very common (>1/10), common (>1/100, <1/10), uncommon (>1/1000, <1/100), rare (>1/10,000, <1/1000), very rare (1/10,000).

……………………………..

 

Reproductive System and Breast Disorders

Very Rare:       Reversible impotence. Breast symptoms in men

 

The safety of ranitidine has been assessed in children aged 0 to 16 years with acid-related disease and was generally well tolerated with an adverse event profile resembling that in adults. There are limited long term safety data available, in particular regarding growth and development.

……………………………..

5.2  Pharmacokinetic properties

 

The bioavailability of ranitidine is consistently about 50%.  Peak concentrations in plasma, normally in the range 300-550ng/ml, occur 2-3 hours after oral administration of a 150mg dose.  Concentrations of ranitidine in plasma are proportional to dose up to and including 300mg.  Ranitidine is not extensively metabolised.  Elimination of the drug is primarily by tubular secretion.  The elimination half-life is 2-3 hours.  In balance studies with 150mg 3H-ranitidine 93% of an intravenous dose was excreted in urine and 5% in faeces; 60-70% of an oral dose was excreted in urine and 26% in faeces. 

 

Analysis of urine excreted in the first 24 hours after dosing showed that 70% of the intravenous dose and 35% of the oral dose were eliminated unchanged. 

 

The metabolism of ranitidine is similar after both oral and intravenous dosing; about 6% of the dose being excreted in urine as the N-oxide, 2% as the S-oxide, 2% as desmethylranitidine and  1 - 2% as the furoic acid analogue.

 

Special Patient Populations

 

Children (3 years and above)

 

Limited pharmacokinetic data have shown that there are no significant differences in half-life (range for children 3 years and above: 1.7 - 2.2 h) and plasma clearance (range for children 3 years and above: 9 - 22 ml/min/kg) between children and healthy adults receiving oral ranitidine when correction is made for body weight.

 

10.  DATE OF (PARTIAL) REVISION OF THE TEXT

 

March 2010

Updated on 30 March 2010 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to dosage and administration

Updated on 4 September 2009 SmPC

Reasons for updating

  • Improved electronic presentation

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Immproved electronical version

Updated on 30 October 2008 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

 

The following Text has been added to section 4.4:

 

Although no clear casual link has been established, a large epidemiological study showed an increased risk of developing community acquired pneumonia in current users of H2 receptor antagonists versus those who had stopped treatment, with an observed adjusted relative risk increase of 1.63 (95% CI, 1.07 2.48). Therefore, in patients with conditions predisposing to the development of pneumonia, such as chronic lung disease, diabetes, or the immunocompromised, there may be an increased risk of developing community acquired pneumonia.

 

In patients such as the elderly, persons with chronic lung disease, diabetes or the immunocompromised, there may be an increased risk of developing community acquired pneumonia in current users of H2 receptor antagonists versus those who had stopped treatment, with an observed adjusted relative risk increase of 4.63 (95% CI, 1.07 2.48).

Updated on 29 October 2008 SmPC

Reasons for updating

  • Correction of spelling/typing errors

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 19 June 2007 SmPC

Reasons for updating

  • Change to section 5.1 - Pharmacodynamic properties

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

5.1 Pharmacodynamic properties

 

Pharmacotherapeutic group: Alimentary tract and metabolism.

ATC code: A02 BA02.

 

Zantac is a specific, rapidly acting histamine H2-antagonist.  It inhibits basal and stimulated secretion of gastric acid reducing both the volume and the acid and pepsin content of the secretion.

 

Although no clear casual link has been established, a large epidemiological study showed showed an increased risk of developing community acquired pneumonia in current users of H2 receptor antagonists versus those who had stopped treatment, with an observed adjusted relative risk increase of 1.63 (95% CI, 1.07 – 2.48).  Therefore, in patients with conditions predisposing to the development of pneumonia, such as chronic lung disease, diabetes, or the immunocompromised, there may be an increased risk of developing community acquired pneumonia.

Updated on 12 March 2007 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 28 September 2006 SmPC

Reasons for updating

  • Change to section 6.3 - Shelf life
  • Change to section 6.5 - Nature and contents of container

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

6.3 Shelf life

        3 years

6.5 nature & contents of the container

Zantac Effervescent Tablets 150mg are packed in white polypropylene tubes fitted with white polyethylene caps filled with silica gel. The tubes are packed into a cardboard carton which has a tamper evident closure. Each tube contains 15 tablets.

Alternatively, Zantac effervescent tablets 150mg are packed in heat-sealable aluminium foil strips. Each aluminium foil strip contains six tablets and five of these strips are packed into a cardboard carton, which has a tamper evident closure.

A sample pack of 6 tablets in a foil strip is also available

Updated on 4 August 2005 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 12 October 2004 PIL

Reasons for updating

  • New PIL for medicines.ie

Updated on 22 October 2003 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 19 August 2003 SmPC

Reasons for updating

  • Improved electronic presentation

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 25 June 2003 SmPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Product subject to medical prescription which may be renewed (B)